K2 Therapeutics seeks to blend China’s speed with global expertise after winning Endpoints 2026 award
read at Endpoints ↗Neutral
K2 Therapeutics, a small drug development company, was named the winner of the Endpoints 2026 award.
The company said it will try to combine the rapid development pace found in China with its own global experience.
By merging these strengths, K2 hopes to accelerate its research programs and bring new medicines to market more quickly.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Endpoints 11 2026 winner K2 Therapeutics looks to marry China’s speed with global expertise”
read at Endpoints ↗82 words · retrieved Sep 25
comments(0)
5-min edit window · permanent after that